top of page

RCUS

Arcus Biosciences

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$1.05B

Burn Rate (Qtr)

$81M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q3 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

RCUS

BPIQ_Logo_RGB-01.jpg

Company Profile

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs.

We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.

Recent Posts

See what the community is saying - click to see full post.

5 Stocks Likely To Move Big On An Early-Stage Readout

5 Stocks Likely To Move Big On An Early-Stage Readout

#AACR24: Hedge Funds Hold These Cancer Companies

#AACR24: Hedge Funds Hold These Cancer Companies

December 2022 Big Mover™ Stocks and Movers to Watch Report

Q1 '22 Perceptive Newly Added Stocks (hedge fund)

bottom of page